✦ LIBER ✦

A meta-analysis of two Irinotecan-based phase III randomized trials for the efficacy and treatment tolerance in older patients with Metastatic Colorectal Cancer (MCRC)

✍ Scribed by Vamvakas, L.; Karampeazis, A.; Boukovinas, I.; Kakolyris, S.; Polyzos, A.; Nintos, G.; Bilidas, T.; Stratigos, M.; Georgoulias, V.; Souglakos, J.

Book ID: 122193038
Publisher: Elsevier
Year: 2013
Tongue: English
Weight: 46 KB
Volume: 4
Category: Article
ISSN: 1879-4068
DOI: 10.1016/j.jgo.2013.09.041

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Addition of Aflibercept to Fluorouracil,

Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

✍ Van Cutsem, E.; Tabernero, J.; Lakomy, R.; Prenen, H.; Prausova, J.; Macarulla, 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 532 KB

A Phase III Randomized, Open-Label, Cont

A Phase III Randomized, Open-Label, Controlled Trial of Chemotherapy and Bevacizumab with or Without Panitumumab in the First-Line Treatment of Patients with Metastatic Colorectal Cancer

✍ Zev Wainberg; J. Randolph Hecht 📂 Article 📅 2006 🏛 CIG Media Group, LP. 🌐 English ⚖ 90 KB

599 ORAL Improved activity with irinotec

599 ORAL Improved activity with irinotecan, oxaliplatin and infusional 5-FU/LV (FOLFOXIRI) compared with FOLFIRI in metastatic colorectal cancer (MCRC): results of a randomized phase III trial by the Gruppo Oncologico Nord Ovest (G.O.N.O.)

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 262 KB

A Phase 2b, Double-Blind, Randomized Stu

A Phase 2b, Double-Blind, Randomized Study Evaluating the Efficacy and Safety of Sorafenib (SOR) Compared With Placebo (PBO) When Administered in Combination With Chemotherapy (Modified FOLFOX6) for First-line Treatment (tx) of Patients (Pts) With Metastatic Colorectal Cancer (mCRC). The RESPECT Trial

✍ J. Tabernero; R. Garcia-Carbonero; C.H. Könne; P.J. O'Dwyer; A. Sobrero; E. Van 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 50 KB

O12 FOLFOXIRI versus FOLFIRI as first li

O12 FOLFOXIRI versus FOLFIRI as first line treatment in metastatic colorectal cancer (MCC): a subgroup analysis for elderly patients of a multicenter randomized phase III trial from the Hellenic Oncology Research Group (HORG)

✍ Vamvakas, L.; Androulakis, N.; Syrigos, K.; Polyzos, A.; Ziras, N.; Athanasiadis 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 62 KB

6096 POSTER FOLFOXIRI (Irinotecan, Oxali

6096 POSTER FOLFOXIRI (Irinotecan, Oxaliplatin, and Infusional 5FU/LV) in Combination With Panitumumab (P) in the First-line Treatment of Metastatic Colorectal Cancer (mCRC) Patients (pts) Selected for KRAS, BRAF, NRas and HRas Mutational Status – a Phase II Study by the G.O.N.O. Group

✍ Fornaro, L.; Loupakis, F.; Lonardi, S.; Masi, G.; Salvatore, L.; Cremolini, C.; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 49 KB